Norfloxacin Therapy for Hepatopulmonary Syndrome: A Pilot Randomized Controlled Trial

Background & Aims The hepatopulmonary syndrome occurs in up to one-third of patients with cirrhosis. Animal models of this disease suggest that endotoxemia might cause nitric oxide–mediated vascular dilatation that can be inhibited by the antibiotic norfloxacin. We sought to test this hypothesis...

Ausführliche Beschreibung